Bayer intends to discontinue partnership with Atara on CAR-T for $670 million

Bayer intends to discontinue partnership with Atara on CAR-T for $670 million
pharmprom.net - Ekaterina • 45d

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative …

Read more on pharmprom.net

    PharmProm.Net - cover
    Magazine
    Avatar - Pharmaceutical Industry in Russia

    Pharmaceutical Industry in Russia flipped this story into PharmProm.Net•45d

    Related storyboards